Archive for the ‘Pharma and Medical Device’ Category

A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara

Posted by Michael A. S. Guth on January 8th, 2026

The MajesTEC-3 results for teclistamab + daratumumab (Tec-Dara)ย in relapsed/refractory multiple myeloma (RRMM) aren’t just an incremental gainโ€”they represent a potential paradigm shift. The FDA’s concurrent award of aย priority review voucherย underscores its transformative potential. Let’s break down the data that’s changing the standard of care: ๐Ÿ”ฌ Unprecedented Efficacy in the 1-3 Prior Lines Setting: โ€ขย PFS:ย Hazard Ratio […]

Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A New Anchor in RRMM: Decoding the Practice-Changing MajesTEC-3 Data for Tec-Dara
Read More »

๐–๐ก๐ฒ “๐•๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐’๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐ ” ๐ข๐ฌ ๐๐จ ๐‹๐จ๐ง๐ ๐ž๐ซ ๐„๐ง๐จ๐ฎ๐ ๐ก ๐Ÿ๐จ๐ซ ๐Ž๐ซ๐ฉ๐ก๐š๐ง ๐†๐๐‚๐‘๐ฌ

Posted by Michael A. S. Guth on January 5th, 2026

๐…๐จ๐ซ ๐ฒ๐ž๐š๐ซ๐ฌ, ๐ญ๐ก๐ž ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐ซ๐ž๐ฅ๐ข๐ž๐ ๐จ๐ง ๐ญ๐ซ๐š๐๐ข๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ฏ๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐ฌ๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐  ๐ญ๐จ ๐Ÿ๐ข๐ง๐ ๐ง๐ž๐ž๐๐ฅ๐ž๐ฌ ๐ข๐ง ๐ญ๐ก๐ž “๐ƒ๐š๐ซ๐ค ๐†๐ž๐ง๐จ๐ฆ๐ž” ๐ก๐š๐ฒ๐ฌ๐ญ๐š๐œ๐ค. ๐๐ฎ๐ญ ๐Ÿ๐จ๐ซ ๐จ๐ซ๐ฉ๐ก๐š๐ง ๐ญ๐š๐ซ๐ ๐ž๐ญ๐ฌ ๐ฅ๐ข๐ค๐ž ๐†๐๐‘๐Ÿ๐Ÿ’๐Ÿ—, ๐ฐ๐ก๐ž๐ซ๐ž ๐ฅ๐ข๐ ๐š๐ง๐ ๐œ๐ก๐ž๐ฆ๐ข๐ฌ๐ญ๐ซ๐ฒ ๐ข๐ฌ ๐ฎ๐ง๐๐ž๐Ÿ๐ข๐ง๐ž๐, ๐ฐ๐ž ๐ง๐ž๐ž๐ ๐ฆ๐จ๐ซ๐ž ๐ญ๐ก๐š๐ง ๐š ๐›๐ž๐ญ๐ญ๐ž๐ซ ๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ž๐ง๐ ๐ข๐ง๐ž. ๐–๐ž ๐ง๐ž๐ž๐ ๐š ๐†๐ž๐ง๐ž๐ซ๐š๐ญ๐ข๐ฏ๐ž ๐„๐ง๐ ๐ข๐ง๐ž. ๐€๐ฌ ๐ฉ๐š๐ซ๐ญ ๐จ๐Ÿ ๐ฆ๐ฒ ๐ฅ๐š๐ญ๐ž๐ฌ๐ญ “๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ข๐š๐ฅ ๐๐ฅ๐ฎ๐ž๐ฉ๐ซ๐ข๐ง๐ญ” ๐Ÿ๐จ๐ซ ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐“๐จ๐๐š๐ฒ, ๐ˆโ€™๐ฏ๐ž ๐จ๐ฎ๐ญ๐ฅ๐ข๐ง๐ž๐ ๐ฐ๐ก๐ฒ […]

Posted in AI Governance, Neuroplasticity, Pharma and Medical Device Comments Off on ๐–๐ก๐ฒ “๐•๐ข๐ซ๐ญ๐ฎ๐š๐ฅ ๐’๐œ๐ซ๐ž๐ž๐ง๐ข๐ง๐ ” ๐ข๐ฌ ๐๐จ ๐‹๐จ๐ง๐ ๐ž๐ซ ๐„๐ง๐จ๐ฎ๐ ๐ก ๐Ÿ๐จ๐ซ ๐Ž๐ซ๐ฉ๐ก๐š๐ง ๐†๐๐‚๐‘๐ฌ
Read More »

๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ

Posted by Michael A. S. Guth on January 3rd, 2026

๐“๐ก๐ž “๐๐ฎ๐ซ๐ฉ๐ฅ๐ž ๐’๐ช๐ฎ๐ข๐ซ๐ซ๐ž๐ฅ” ๐“๐š๐ฅ๐ž๐ง๐ญ ๐†๐š๐ฉ Recruiters often call this the โ€œpurple squirrelโ€ profile: a “unicorn” blending deep regulatory strategy, therapeutic area such as neurology research expertise, with a fundamental understanding of AI application.

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐…๐ซ๐จ๐ฆ ๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐œ๐ž ๐ญ๐จ ๐€๐ ๐ž๐ง๐œ๐ฒ: ๐–๐ก๐ฒ ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐‚๐š๐ซ๐ž ๐†๐ข๐š๐ง๐ญ๐ฌ ๐๐ž๐ž๐ ๐‚๐จ๐ฆ๐›๐ข๐ง๐ž๐ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ/๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ ๐€๐ซ๐ž๐š/๐€๐ˆ ๐’๐ค๐ข๐ฅ๐ฅ๐ž๐ ๐“๐š๐ฅ๐ž๐ง๐ญ
Read More »

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy

Posted by Michael A. S. Guth on January 3rd, 2026

Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy In my independent review of the CARES-310 trial (Camrelizumab-Rivoceranib), I analyzed a common pitfall in modern drug development: the reliance on 16-week primary endpoints to justify long-term therapeutic narratives. While a 16-week data cut can deliver a clean p-value for a regulatory […]

Posted in AI Governance, Pharma and Medical Device, Regulatory Medical Writing Comments Off on Beyond the 16-Week Snapshot: Why Data Snapshots Mask the Reality of Chronic Therapy
Read More »

Pharyngeal Electrical Stimulation (PES) for Neurogenic Dysphagia: An Overview

Posted by Michael A. S. Guth on December 20th, 2025

Pharyngeal Electrical Stimulation (PES) for Neurogenic Dysphagia: An Overview Introduction to Neurogenic Dysphagia and the Need for Restorative Therapy Neurogenic dysphagia (ND) is a swallowing impairment resulting from neurological damage, most commonly caused by stroke, multiple sclerosis (MS), traumatic brain injury, or neurodegenerative diseases.1 ND is associated with severe complications, including malnutrition, dehydration, and aspiration […]

Posted in Neuroplasticity, Pharma and Medical Device Comments Off on Pharyngeal Electrical Stimulation (PES) for Neurogenic Dysphagia: An Overview
Read More »

๐“๐ก๐ž ๐„๐ง๐ ๐ข๐ง๐ž ๐๐ž๐ก๐ข๐ง๐ ๐ญ๐ก๐ž ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐ž: ๐–๐ก๐ฒ ๐Œ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐‚๐ž๐ฅ๐ฅ ๐„๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐  ๐ข๐ฌ ๐‚๐ž๐ง๐ญ๐ซ๐š๐ฅ ๐ญ๐จ ๐Œ๐จ๐๐ž๐ซ๐ง ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ.

Posted by Michael A. S. Guth on December 18th, 2025

๐“๐ก๐ž ๐„๐ง๐ ๐ข๐ง๐ž ๐๐ž๐ก๐ข๐ง๐ ๐ญ๐ก๐ž ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐ž: ๐–๐ก๐ฒ ๐Œ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐‚๐ž๐ฅ๐ฅ ๐„๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐  ๐ข๐ฌ ๐‚๐ž๐ง๐ญ๐ซ๐š๐ฅ ๐ญ๐จ ๐Œ๐จ๐๐ž๐ซ๐ง ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ. ๐ˆ๐ง ๐ญ๐ก๐ž ๐ซ๐š๐œ๐ž ๐ญ๐จ ๐๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ ๐œ๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ ๐ญ๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ, ๐ญ๐ก๐ž ๐ž๐ฑ๐ฉ๐ซ๐ž๐ฌ๐ฌ๐ข๐จ๐ง ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ ๐ข๐ฌ ๐š ๐œ๐ซ๐ข๐ญ๐ข๐œ๐š๐ฅ ๐ฌ๐ญ๐ซ๐š๐ญ๐ž๐ ๐ข๐œ ๐œ๐ก๐จ๐ข๐œ๐ž. ๐…๐จ๐ซ ๐ฆ๐š๐ง๐ฒ ๐๐ซ๐ฎ๐  ๐œ๐š๐ง๐๐ข๐๐š๐ญ๐ž๐ฌโ€”๐ž๐ฌ๐ฉ๐ž๐œ๐ข๐š๐ฅ๐ฅ๐ฒ ๐š๐ง๐ญ๐ข๐›๐จ๐๐ข๐ž๐ฌ, ๐Ÿ๐ฎ๐ฌ๐ข๐จ๐ง ๐ฉ๐ซ๐จ๐ญ๐ž๐ข๐ง๐ฌ, ๐š๐ง๐ ๐œ๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ ๐ž๐ง๐ณ๐ฒ๐ฆ๐ž๐ฌโ€”๐ฆ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐œ๐ž๐ฅ๐ฅ๐ฌ ๐š๐ซ๐ž ๐ง๐จ๐ง-๐ง๐ž๐ ๐จ๐ญ๐ข๐š๐›๐ฅ๐ž. ๐‡๐ž๐ซ๐žโ€™๐ฌ ๐ฐ๐ก๐ฒ ๐จ๐ฎ๐ซ ๐Ÿ๐จ๐œ๐ฎ๐ฌ ๐ก๐š๐ฌ ๐ข๐ง๐ญ๐ž๐ง๐ฌ๐ข๐Ÿ๐ข๐ž๐ ๐จ๐ง ๐ž๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ ๐ข๐ญ๐ฌ๐ž๐ฅ๐Ÿ: ๐…๐ข๐๐ž๐ฅ๐ข๐ญ๐ฒ […]

Posted in Pharma and Medical Device Comments Off on ๐“๐ก๐ž ๐„๐ง๐ ๐ข๐ง๐ž ๐๐ž๐ก๐ข๐ง๐ ๐ญ๐ก๐ž ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐ž: ๐–๐ก๐ฒ ๐Œ๐š๐ฆ๐ฆ๐š๐ฅ๐ข๐š๐ง ๐‚๐ž๐ฅ๐ฅ ๐„๐ง๐ ๐ข๐ง๐ž๐ž๐ซ๐ข๐ง๐  ๐ข๐ฌ ๐‚๐ž๐ง๐ญ๐ซ๐š๐ฅ ๐ญ๐จ ๐Œ๐จ๐๐ž๐ซ๐ง ๐ƒ๐ซ๐ฎ๐  ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ.
Read More »

COVID-19 Treatment Strategies: Dec 2025 update

Posted by Michael A. S. Guth on December 13th, 2025
Moving Simulation of SARS-CoV-2 Delta Variant

Image:ย  Computerย Simulation of SARS-CoV-2. Reprinted with kind permission of Janet Iwasa of http://animationlab.utah.edu/cova Should I Get a COVID-19 Vaccine in December 2025 or January 2026? As we move through the winter of 2025-2026, the question of whether to get a COVID-19 vaccine is highly relevant, especially as respiratory viruses typically peak during this time. The […]

Posted in Featured, Pharma and Medical Device Tags: , , , , , , , , , Comments Off on COVID-19 Treatment Strategies: Dec 2025 update
Read More »

๐€๐ซ๐ž ๐œ๐ก๐ข๐œ๐ค๐ž๐ง ๐ž๐ ๐ ๐ฌ ๐ญ๐ก๐ž ๐ฅ๐ž๐š๐๐ข๐ง๐  ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž ๐จ๐Ÿ ๐š๐ซ๐š๐œ๐ก๐ข๐๐จ๐ง๐ข๐œ ๐š๐œ๐ข๐ ๐ข๐ง ๐ญ๐ก๐ž ๐€๐ฆ๐ž๐ซ๐ข๐œ๐š๐ง ๐๐ข๐ž๐ญ? ๐‡๐จ๐ฐ ๐ข๐ฌ ๐š๐ซ๐š๐œ๐ก๐ข๐๐จ๐ง๐ข๐œ ๐š๐œ๐ข๐ ๐ฅ๐ข๐ง๐ค๐ž๐ ๐ญ๐จ ๐ข๐ง๐Ÿ๐ฅ๐š๐ฆ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐ญ๐ก๐ž ๐š๐ ๐ข๐ง๐  ๐š๐ง๐ ๐ฉ๐ซ๐ž๐ฆ๐š๐ญ๐ฎ๐ซ๐ž ๐š๐ ๐ข๐ง๐  ๐จ๐Ÿ ๐ญ๐ก๐ž ๐›๐จ๐๐ฒ?

Posted by Michael A. S. Guth on November 24th, 2025

Yes, chicken and eggs are major sources of arachidonic acid in the American diet, with chicken often cited as the top source and eggs as a very significant one.ย Excess arachidonic acid is linked to inflammation through the production of inflammatoryย eicosanoids, which can contribute to chronic diseases and may be associated with premature aging. The body […]

Posted in Pharma and Medical Device Comments Off on ๐€๐ซ๐ž ๐œ๐ก๐ข๐œ๐ค๐ž๐ง ๐ž๐ ๐ ๐ฌ ๐ญ๐ก๐ž ๐ฅ๐ž๐š๐๐ข๐ง๐  ๐ฌ๐จ๐ฎ๐ซ๐œ๐ž ๐จ๐Ÿ ๐š๐ซ๐š๐œ๐ก๐ข๐๐จ๐ง๐ข๐œ ๐š๐œ๐ข๐ ๐ข๐ง ๐ญ๐ก๐ž ๐€๐ฆ๐ž๐ซ๐ข๐œ๐š๐ง ๐๐ข๐ž๐ญ? ๐‡๐จ๐ฐ ๐ข๐ฌ ๐š๐ซ๐š๐œ๐ก๐ข๐๐จ๐ง๐ข๐œ ๐š๐œ๐ข๐ ๐ฅ๐ข๐ง๐ค๐ž๐ ๐ญ๐จ ๐ข๐ง๐Ÿ๐ฅ๐š๐ฆ๐ฆ๐š๐ญ๐ข๐จ๐ง ๐š๐ง๐ ๐ญ๐ก๐ž ๐š๐ ๐ข๐ง๐  ๐š๐ง๐ ๐ฉ๐ซ๐ž๐ฆ๐š๐ญ๐ฎ๐ซ๐ž ๐š๐ ๐ข๐ง๐  ๐จ๐Ÿ ๐ญ๐ก๐ž ๐›๐จ๐๐ฒ?
Read More »

BLA: Transforming Data into Regulatory Success

Posted by Michael A. S. Guth on November 7th, 2025

๐‚๐Œ๐‚ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐’๐ญ๐ซ๐š๐ญ๐ž๐ ๐ฒ ๐ข๐ง ๐š ๐ง๐ฎ๐ญ๐ฌ๐ก๐ž๐ฅ๐ฅ: ๐ˆ๐ญ’๐ฌ ๐ญ๐ก๐ž ๐š๐ซ๐ญ ๐จ๐Ÿ ๐ญ๐ฎ๐ซ๐ง๐ข๐ง๐  ๐œ๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ ๐ฆ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐  ๐๐š๐ญ๐š ๐ข๐ง๐ญ๐จ ๐š ๐ฌ๐ญ๐จ๐ซ๐ฒ ๐จ๐Ÿ ๐œ๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐š๐ง๐ ๐œ๐จ๐ง๐ฌ๐ข๐ฌ๐ญ๐ž๐ง๐œ๐ฒ ๐ญ๐ก๐š๐ญ ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฌ ๐œ๐š๐ง ๐ญ๐ซ๐ฎ๐ฌ๐ญ. ๐…๐จ๐ซ ๐š ๐๐ก๐š๐ฌ๐ž ๐Ÿ‘ ๐›๐ข๐จ๐ฅ๐จ๐ ๐ข๐œ, ๐ญ๐ก๐ข๐ฌ ๐ฆ๐ž๐š๐ง๐ฌ: โœ… ๐…๐ซ๐จ๐ฆ ๐ƒ๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ ๐ญ๐จ ๐‚๐จ๐ฆ๐ฆ๐ž๐ซ๐œ๐ข๐š๐ฅ: ๐‰๐ฎ๐ฌ๐ญ๐ข๐Ÿ๐ฒ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฌ๐ก๐ข๐Ÿ๐ญ ๐ญ๐จ ๐š ๐ฏ๐š๐ฅ๐ข๐๐š๐ญ๐ž๐, ๐ฌ๐œ๐š๐ฅ๐š๐›๐ฅ๐ž ๐ฉ๐ซ๐จ๐œ๐ž๐ฌ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐ฌ๐œ๐ข๐ž๐ง๐œ๐ž-๐›๐š๐œ๐ค๐ž๐ ๐œ๐จ๐ฆ๐ฉ๐š๐ซ๐š๐›๐ข๐ฅ๐ข๐ญ๐ฒ ๐ฉ๐ฅ๐š๐ง. โœ… ๐๐ฎ๐ข๐ฅ๐๐ข๐ง๐  ๐ญ๐ก๐ž ๐‚๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐๐š๐ซ๐ซ๐š๐ญ๐ข๐ฏ๐ž: […]

Posted in Pharma and Medical Device Comments Off on BLA: Transforming Data into Regulatory Success
Read More »

Options After Stage 4 Glioblastoma Diagnosis and Resection Surgery

Posted by Michael A. S. Guth on July 5th, 2025

I’m deeply sorry to hear about your father’s diagnosis. Glioblastoma (GBM), especially grade 4, is an aggressive brain cancer, but there are treatment options and emerging therapies that may offer hope. Below is a structured overview ofย standard treatments,ย promising clinical trials, andย cutting-edge therapiesย you can explore while awaiting the histology report. 1. Standard of Care (Post-Surgery) Once […]

Posted in Pharma and Medical Device Comments Off on Options After Stage 4 Glioblastoma Diagnosis and Resection Surgery
Read More »
« Older Entries
Newer Entries »